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A long-term cohort study of working men in Israel found that smokers who reduced their cigarette consumption
had lower subsequent mortality rates than those who did not. We conducted comparable analyses in 2 populations
of smokers in Scotland. The Collaborative Study included 1,524 men and women aged 40–65 years in a working
population who were screened twice, in 1970–1973 and 1977. The Renfrew/Paisley Study included 3,730 men
and women aged 45–64 years in a general population who were screened twice, in 1972–1976 and 1977–
1979. Both groups were followed up through 2010. Subjects were categorized by smoking intensity at each
screening as smoking 0, 1–10, 11–20, or ≥21 cigarettes per day. At the second screening, subjects were catego-
rized as having increased, maintained, or reduced their smoking intensity or as having quit smoking between the
first and second screenings. There was no evidence of lower mortality in all reducers compared with maintainers.
Multivariate adjusted hazard ratios of mortality were 0.91 (95% confidence interval (CI): 0.75, 1.10) in the Collabo-
rative Study and 1.08 (95% CI: 0.97, 1.20) in the Renfrew/Paisley Study. There was clear evidence of lower mortal-
ity among quitters in both the Collaborative Study (hazard ratio = 0.66, 95% CI: 0.56, 0.78) and the Renfrew/
Paisley Study (hazard ratio = 0.75, 95% CI: 0.67, 0.84). In the Collaborative Study only, we observed lower mortal-
ity similar to that of quitters among heavy smokers (≥21 cigarettes/day) who reduced their smoking intensity.
These inconclusive results support the view that reducing cigarette consumption should not be promoted as a
means of reducing mortality, although it may have a valuable role as a step toward smoking cessation.
cohort studies; harm reduction; longevity; mortality; smoking; smoking cessation
Abbreviations: CI, confidence interval; HR, hazard ratio; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10,
International Classification of Diseases, Tenth Revision.
Despite clear evidence that smoking cessation brings sub-
stantial health beneﬁts and ﬁnancial savings, many smokers
are unable or unwilling to quit. Consequently, researchers
have tried to establish whether reducing the number of ciga-
rettes smoked could bring about sufﬁcient long-term health
beneﬁts to be recommended as a worthwhile alternative to
quitting. A large prospective cohort study in Denmark with
a mean of 15 years’ follow-up found no evidence that heavy
smokers who reduced their daily number of cigarettes had a
lower risk of death from all causes or of fatal or nonfatal
myocardial infarction (1, 2). A systematic review of the
health beneﬁts of smoking reduction identiﬁed 24 other
studies, most of which were small and with short follow-up (3).
It concluded that a substantial reduction in smoking seemed
to have a small health beneﬁt, but more research was needed
to determine the long-term effects. Two other large prospec-
tive cohort studies found that smoking reduction did not
lower the risk of death from all causes (4) or the incidence of
stroke or myocardial infarction (5). However, a recent cohort
study of working Israeli men who were recruited in 1963,
rescreened in 1965, and followed up for 32 years found that
smoking reducers had signiﬁcantly lower hazard ratios for
mortality than did maintainers (6). The apparent beneﬁt of
reducing smoking was seen primarily in heavy smokers and
for cardiovascular disease mortality. In light of these results,
the authors suggested that reducing the number of cigarettes
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smoked was a plausible risk-reduction strategy for heavy
smokers who are unable to quit. Advocating reduction rather
than cessation for some smokers would be a major shift in
approach that should have solid support from several rigor-
ous studies. In an attempt to reproduce the Israeli ﬁndings,
we applied the methodology of that study to 2 comparable
cohorts in Scotland that were recruited and rescreened in the
1970s and followed up until the end of 2010.
MATERIALS AND METHODS
Participants were from 2 of the Midspan prospective
cohort studies, which originated in the postwar effort to con-
trol pulmonary tuberculosis by screening with mass mini-
ature radiography (7). Recruitment for the Collaborative
Study of working men (n = 6,022) and women (n = 1,006)
took place between 1970 and 1973 in 27 workplaces in the
central belt of Scotland (8). Recruitment for the Renfrew/
Paisley Study of the general population (7,049 men and 8,353
women) took place between 1972 and 1976 in 2 Scottish
towns (9). Second screenings took place in 1977 for the Col-
laborative Study and in 1977–1979 for the Renfrew/Paisley
Study. Participants in both studies completed similar question-
naires and had similar screening examinations. The present
analysis used data from men and women who were cigarette
smokers at the ﬁrst screening and who took part in the second
screening.
The questionnaires at both screenings included questions
on smoking behavior, occupation, diabetes, angina, and severe
chest pain lasting for at least 30 minutes. At the ﬁrst screening,
blood pressure, height, and weight were measured, electrocar-
diography was performed, and a blood sample was taken to test
for plasma cholesterol levels; these procedures were repeated at
the second screening except for cholesterol measurements.
As in the Israeli study, detailed questions about smoking
behavior allowed subjects to be categorized as smoking 1–
10, 11–20, or ≥21 cigarettes per day at the 2 screening occa-
sions, or as having quit smoking by the second screening
(6). Smokers were deﬁned at the second screening as having
increased (moved to a higher category), maintained (stayed
in the same category), or reduced (moved to a lower cate-
gory) their smoking intensity or as having quit smoking. For
additional analyses, the “reduced” group was subdivided into
those who reduced from ≥21 cigarettes/day (heavy smokers)
or from ≤20 cigarettes/day (lighter smokers).
We deﬁned 6 social class groups based on occupation
according to the General Register Ofﬁce Classiﬁcation of Occu-
pations (10) ranging from I (professional) to V (unskilled),
with manual social class deﬁned as III manual (skilled man-
ual), IV (partly skilled), and V (unskilled). Women who clas-
siﬁed themselves as “housewives” in the Renfrew/Paisley
Study were allocated the social classes of their husbands.
Diabetes was self reported. Angina was deﬁned according to
the Rose questionnaire (11). At the screening examination,
blood pressure was measured with participants seated.
Height and weight were measured, and body mass index
(weight (kg)/height (m)2) was calculated. Ischemia on elec-
trocardiogram was deﬁned as any of the following Minne-
sota codes: 1.1–1.3, 4.1–4.4, 5.1–5.3, or 7.1 (12). Preexisting
coronary heart disease was deﬁned as any angina (deﬁnite or
possible (13)), severe chest pain lasting at least 30 minutes, or
ischemia on electrocardiogram.
Mortality follow-up was established by ﬂagging partici-
pant data in the National Health Service Central Register.
Dates and causes of death were obtained until the end of
2010. Cardiovascular disease mortality was deﬁned as coro-
nary heart disease (International Classiﬁcation of Diseases,
Ninth Revision (ICD-9), codes 410–414 or International
Classiﬁcation of Diseases, Tenth Revision (ICD-10), codes
I20–I25) or stroke (ICD-9 codes 430–438 or ICD-10 codes
I60–I69 or G45). Non–cardiovascular disease mortality was
deﬁned as all other causes of death. Lung cancer mortality
was deﬁned as ICD-9 code 162 or ICD-10 codes C33–C34.
Nine Collaborative Study and 23 Renfrew/Paisley Study par-
ticipants who left the United Kingdom were censored at
their leaving dates.
The age range for participation in the Renfrew/Paisley
Study was 45–64 years (mean = 53 years). Collaborative
Study participants were included in this analysis if they were
aged 40 years or older at the ﬁrst screening (mean = 49
years, maximum = 65 years) to achieve a similar age range
to that of participants in the Israeli study (6). After the exclu-
sion of participants who were lost to follow-up (1 Collabora-
tive Study and 4 Renfrew/Paisley Study participants), there
were 1,524 (1,299 male and 225 female) Collaborative
Study and 3,730 (1,878 male and 1,852 female) Renfrew/
Paisley Study participants who were current smokers at the
ﬁrst screening and who took part in the second screening.
Statistical analyses were conducted by using Stata, version
11, software (StataCorp LP, College Station, Texas), and all
P values were 2-sided. Means and percentages of risk factors
were standardized by 5-year age groups. Tests for trends
across smoking intensity categories were calculated by using
regression analysis for continuous variables or logistic regres-
sion analysis for discrete variables. Cox proportional hazards
regression models were used to calculate the hazard ratios of
mortality for each smoking intensity category and to calcu-
late P values for trend by using smoking intensity as a con-
tinuous variable. The proportional hazards assumption was
checked by using Schoenfeld residuals. Analyses of mortality
from cardiovascular disease and non–cardiovascular disease
accounted for competing risks by using the stcrreg proce-
dure in Stata, version 11, software, which uses the method-
ology of Fine and Gray (14). Participants who maintained
their smoking intensity were considered the baseline group.
The ﬁrst model included adjustments for age at the second
screening, social class, and number of cigarettes smoked at
the ﬁrst screening. The second model also adjusted for sys-
tolic blood pressure, body mass index, diabetes, and preex-
isting coronary heart disease at the second screening and
plasma cholesterol level at ﬁrst screening. The few missing
variables (0.6% in the Collaborative Study and 3.2% in
the Renfrew/Paisley Study) were replaced by the sex- and
study-speciﬁc mean (or mode for social class). Follow-up
was from the date of the second screening until the date of
death, date of leaving the United Kingdom, or December 31,
2010. Interactions with sex were not signiﬁcant (P for inter-
action for all-cause mortality was 0.15 in the Collaborative
Study and 0.52 in the Renfrew/Paisley Study), so results are
presented with data from men and women combined, and
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analyses included a term for sex. Results for men and women
are presented separately in Web Tables 1–3 available at http://
aje.oxfordjournals.org/.
Logistic regression was used to calculate the odds ratios of
survival by smoking intensity category to age 75 years in both
studies and to age 80 years in the Renfrew/Paisley Study only
(because 23 surviving Collaborative Study participants had not
reached age 80 years at the end of follow-up). Tests for trend
usedsmokingintensityasacontinuousvariable.Participantswho
had left the United Kingdom during follow-up were excluded
from these analyses only, because there was no information
on death status. Higher odds ratios represent better outcomes
in these analyses, in contrast to hazard ratios of mortality, in
which higher hazard ratios represent worse outcomes.
Finally, the 2 studies were combined and analyzed with a
term for study included. There were 3 men who participated
in both studies; only their Collaborative Study data were used
in these joint analyses because that study was conducted
ﬁrst (15). Interactions with study were not signiﬁcant, apart
from analysis of all-cause mortality with the “reduced” cate-
gory subdivided into heavy and lighter smokers (P for
interaction = 0.017); therefore, these analyseswere conducted
separately for the 2 studies. Analyses were repeated, exclud-
ing deaths in the ﬁrst 3 years to address reverse causation.
Further analyses included adjustment for duration of smoking
from smoking initiation to ﬁrst screening, which excluded
16 Renfrew/Paisley Study participants with missing data on
age at smoking initiation.
RESULTS
Smoking categories at the ﬁrst and second screenings are
shown in Tables 1 and 2 for the Collaborative and Renfrew/
Paisley Studies, respectively. In the Collaborative Study,
13.8% of subjects increased, 59.2% maintained, and 9.6%
reduced their cigarette consumption, and 17.3% quit smok-
ing between the 2 screenings (Table 3). In the Renfrew/
Paisley Study, 9.9% of subjects increased, 64.6% maintained,
and 12.6% reduced their cigarette consumption, and 13.0%
quit smoking. Differences in risk factors among the smoking
change groups were apparent in participants who quit smoking.
Quitters in the Collaborative Study had higher cholesterol levels
and bodymass index values, and fewer were frommanual social
classes. Quitters in the Renfrew/Paisley Study had higher sys-
tolic blood pressure and body mass index values.
During a median follow-up of 21.1 (maximum, 33.9) years
in the Collaborative Study, 1,252 participants (82%) died. Dur-
ing a median follow-up of 18.7 (maximum, 33.8) years in the
Renfrew/Paisley Study, 3,187 participants (85%) died. There
was no evidence of lower mortality in those who reduced ciga-
rette consumption compared with those who maintained ciga-
rette consumption. The multivariate adjusted hazard ratios of
mortality were 0.91 (95% conﬁdence interval (CI): 0.75, 1.10)
in the Collaborative Study and 1.08 (95% CI: 0.97, 1.20) in
the Renfrew/Paisley Study (Table 4). Renfrew/Paisley Study
participants who increased their smoking intensity had higher
hazard ratios of mortality (multivariate adjusted hazard ratio
(HR) = 1.17, 95% CI: 1.04, 1.32), but no signiﬁcant rate was
seen for increasers in the Collaborative Study. There was clear
evidence of lower mortality in quitters (multivariate adjusted
HRs of 0.66 (95% CI: 0.56, 0.78) and 0.75 (95% CI: 0.67,
0.84) in theCollaborative andRenfrew/Paisley Studies, respec-
tively). Additional adjustment for smoking duration had a
negligible effect; the multivariate adjusted hazard ratio for
reducers was 0.92 (95% CI: 0.76, 1.11) compared with
0.91 (95% CI: 0.75, 1.10) without this adjustment for the
Table 1. Cigarette Smoking Intensity at a Second Screening (in 1977) Compared With That at a First Screening (in
1970–1973) in the Collaborative Study, Scotland
Smoking at
First Screening,
cigarettes/day
Smoking at Second Screening, cigarettes/day
0 1–10 11–20 ≥21 Total
No. % No. % No. % No. % No. %
Men and women
(n = 1,524)
1–10 60 3.9 160 10.5 59 3.9 8 0.5 287 18.8
11–20 140 9.2 85 5.6 526 34.5 144 9.4 895 58.7
≥21 64 4.2 4 0.3 58 3.8 216 14.2 342 22.4
Total 264 17.3 249 16.3 643 42.2 368 24.1 1,524 100
Men (n = 1,299)
1–10 57 4.4 133 10.2 43 3.3 6 0.5 239 18.4
11–20 129 9.9 70 5.4 431 33.2 125 9.6 755 58.1
≥21 64 4.9 4 0.3 52 4.0 185 14.2 305 23.5
Total 250 19.2 207 15.9 526 40.5 316 24.3 1,299 100
Women (n = 225)
1–10 3 1.3 27 12.0 16 7.1 2 0.9 48 21.3
11–20 11 4.9 15 6.7 95 42.2 19 8.4 140 62.2
≥21 0 0 0 0 6 2.7 31 13.8 37 16.4
Total 14 6.2 42 18.7 117 52.0 52 23.1 225 100
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Collaborative Study and 1.07 (95% CI: 0.96, 1.19) compared
with 1.07 (95% CI: 0.97, 1.19) for the Renfrew/Paisley Study
(excluding 16 subjects with missing data).
We analyzed heavy smokers (≥21 cigarettes/day) who
reduced smoking intensity separately from lighter smokers
(≤20 cigarettes/day) who reduced smoking intensity and
obtained contrasting results. In the Collaborative Study, there
was a signiﬁcantly lower multivariate adjusted hazard ratio
of mortality for the heavy smokers who reduced smoking
intensity (HR = 0.67, 95% CI: 0.50, 0.90), which was similar
to that for quitters. The lighter smokers who reduced smok-
ing intensity had a nonsigniﬁcant hazard ratio of 1.17 (95%
CI: 0.92, 1.48). In the Renfrew/Paisley Study, therewas no sug-
gestion of lower mortality for smoking reduction among either
heavy smokers (HR = 1.14, 95% CI: 0.97, 1.33) or lighter
smokers (HR = 1.04, 95% CI: 0.91, 1.19) (data not shown).
Hazard ratios of cardiovascular disease mortality that used
competing risk models were no different across the smoking
intensity categories in either cohort (Table 4). There was lower
mortality from non–cardiovascular disease causes among quit-
ters in both cohorts but not among reducers when using com-
peting risk models. In the combined studies, there was lower
mortality from lung cancer among quitters (multivariate
adjusted HR = 0.53, 95% CI: 0.39, 0.71) but not among
reducers (multivariate adjusted HR = 0.91, 95% CI: 0.70,
1.19) (data not shown). The overall results were similar for
men and women separately (Web Table 1). Results were
also similar when both cohorts were combined (Table 5 for
men and women, Web Table 2 for men and women sepa-
rately). The exclusion of deaths in the ﬁrst 3 years had essen-
tially no effect on the results (data not shown).
The multivariate odds ratios of surviving to age 75 years
were no higher in reducers than in maintainers in both
studies. The odds ratios were 1.07 (95% CI: 0.74, 1.54) in
the Collaborative Study and 0.87 (95% CI: 0.7, 1.07) in the
Renfrew/Paisley Study (Table 6). The multivariate adjusted
odds of surviving to age 75 years were lower for Collabora-
tive Study participants who increased their smoking. Collab-
orative and Renfrew/Paisley Study participants who quit
smoking had higher odds of surviving to age 75 years. Com-
bining the 2 cohorts produced similar results. Survival to age
80 years was higher among Renfrew/Paisley Study partici-
pants who quit smoking (odds ratio = 1.64, 95% CI: 1.33,
2.02). Results for men and women are shown separately in
Web Table 3.
DISCUSSION
In this long-term prospective study of both working and
general population cohorts, we were unable to detect a sig-
niﬁcant overall long-term survival beneﬁt among smokers
who reported reducing their daily consumption of cigarettes
between 2 screenings a few years apart. Our results can be
usefully compared with those of a recently published Israeli
study of comparable size, methodology, and duration of
follow-up, which found lower long-term all-cause and car-
diovascular disease mortality rates among smoking reducers
(6). Two other large cohort studies found that smoking
reduction did not reduce the risk of dying (4) or of experi-
encing a stroke or myocardial infarction (5). A third large
cohort study found that hazard ratios of all causes of death
and fatal or nonfatal myocardial infarction were not reduced
after 15.5 years of follow-up (1, 2). The main features and
outcomes of the 6 cohort studies are summarized in Table 7.
All studies used essentially the same methods of 2 screenings
a few years apart and subsequent follow-up. Five used death
Table 2. Cigarette Smoking Intensity at a Second Screening (in 1977–1979) Compared With That at a First
Screening (in 1972–1976) in the Renfrew/Paisley Study, Scotland
Smoking at
First Screening,
cigarettes/day
Smoking at Second Screening, cigarettes/day
0 1–10 11–20 ≥21 Total
No. % No. % No. % No. % No. %
Men and women
(n = 3,730)
1–10 166 4.5 483 12.9 169 4.5 9 0.2 827 22.2
11–20 213 5.7 272 7.3 1,521 40.8 190 5.1 2,196 58.9
≥21 105 2.8 6 0.2 191 5.1 405 10.9 707 19.0
Total 484 13.0 761 20.4 1,881 50.4 604 16.2 3,730 100
Men (n = 1,878)
1–10 53 2.8 133 7.1 71 3.8 7 0.4 264 14.1
11–20 141 7.5 102 5.4 690 36.7 122 6.5 1,055 56.2
≥21 91 4.8 5 0.3 135 7.2 328 17.5 559 29.8
Total 285 15.2 240 12.8 896 47.7 457 24.3 1,878 100
Women (n = 1,852)
1–10 113 6.1 350 18.9 98 5.3 2 0.1 563 30.4
11–20 72 3.9 170 9.2 831 44.9 68 3.7 1,141 61.6
≥21 14 0.8 1 0.1 56 3.0 77 4.2 148 8.0
Total 199 10.7 521 28.1 985 53.2 147 7.9 1,852 100
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Table 3. Risk Factorsa According to Changes in Smoking Intensity Between 2 Screenings of the Collaborative (in 1970–1973 and 1977) and Renfrew/Paisley (in 1972–1976 and 1977–
1979) Studies, Scotland
Smoking Intensity
Changes by Cohort
Total Age, yearsb Systolic BloodPressure, mm Hgb
Cholesterol,
mmol/Lc
Body Mass
Indexb,d
Preexisting
Coronary Heart
Diseaseb
Manual
Social Classc
No. % Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI % 95% CI % 95% CI
Collaborative Study
Cohort
Increased 211 13.8 52.9 52.3, 53.6 142.4 139.6, 145.2 5.75 5.60, 5.89 24.9 24.5, 25.2 23.4 17.8, 29.1 61.5 54.8, 68.2
Maintained 902 59.2 54.2 53.8, 54.5 142.4 141.1, 143.7 5.67 5.60, 5.73 24.5 24.3, 24.7 22.5 19.7, 25.2 68.0 64.9, 71.0
Reduced 147 9.6 55.3 54.5, 56.0 145.7 142.0, 149.4 5.77 5.59, 5.95 25.1 24.6, 25.6 27.5 20.2, 34.8 73.2 65.8, 80.7
Quit 264 17.3 53.7 53.1, 54.3 145.3 142.9, 147.7 5.86 5.73, 5.99 26.1 25.7, 26.4 26.0 20.8, 31.1 58.5 52.6, 64.4
Ptrend 0.16 0.037 0.045 <0.0001 0.12 0.26
Renfrew/Paisley
Study
Cohort
Increased 368 9.9 56.5 56.0, 57.1 144.2 142.0, 146.5 6.05 5.92, 6.17 24.5 24.1, 24.9 31.0 26.2, 35.7 67.8 62.8, 72.7
Maintained 2,409 64.6 57.5 57.3, 57.7 145.4 144.6, 146.2 6.13 6.08, 6.17 24.6 24.4, 24.7 30.2 28.4, 32.0 61.2 59.2, 63.2
Reduced 469 12.6 58.8 58.3, 59.3 143.6 141.6, 145.5 6.10 6.01, 6.20 24.5 24.2, 24.9 33.1 28.8, 37.4 64.7 60.2, 69.2
Quit 484 13.0 59.0 58.5, 59.5 149.6 147.8, 151.5 6.07 5.98, 6.16 26.2 25.9, 26.6 33.2 28.9, 37.5 59.4 55.0, 63.9
Ptrend <0.0001 0.003 0.72 <0.0001 0.20 0.12
Abbreviation: CI, confidence interval.
a Adjusted for age at the second screening (except mean age).
b Measured at second screening.
c Measured at first screening.
d Body mass index is weight (kg)/height (m)2.
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Table 4. Hazard Ratios of All-Cause, Cardiovascular Disease, and Non–Cardiovascular Disease Mortality According to Changes in Smoking Intensity Between 2 Screenings of the
Collaborative (in 1970–1973 and 1977) and Renfrew/Paisley (in 1972–1976 and 1977–1979) Studies, Scotland
Smoking Intensity
Changes by Cohort
Total All-Cause Mortality Cardiovascular Disease Mortalitya Non–Cardiovascular Disease Mortalitya
No. %
Person-
Years
No. of
Deaths
Rateb HRc 95% CI HRd 95% CI
No. of
Deaths
Rateb HRc 95% CI HRd 95% CI
No. of
Deaths
Rateb HRc 95% CI HRd 95% CI
Collaborative
Study Cohort
Increased 211 13.8 4,215 172 408.0 1.14 0.96, 1.35 1.15 0.97, 1.35 67 159.0 1.02 0.78, 1.34 0.99 0.75, 1.30 105 249.1 1.11 0.89, 1.38 1.12 0.90, 1.39
Maintained 902 59.2 18,538 765 412.7 1 Referent 1 Referent 301 162.4 1 Referent 1 Referent 464 250.3 1 Referent 1 Referent
Reduced 147 9.6 2,849 128 449.2 0.96 0.79, 1.16 0.91 0.75, 1.10 52 182.5 1.01 0.74, 1.36 0.90 0.66, 1.22 76 266.7 0.97 0.76, 1.24 1.0 0.78, 1.28
Quit 264 17.3 6,092 187 307.0 0.69 0.59, 0.81 0.66 0.56, 0.78 83 136.3 0.93 0.73, 1.19 0.84 0.66, 1.08 104 170.7 0.71 0.57, 0.88 0.74 0.59, 0.92
Ptrend <0.0001 <0.0001 0.56 0.19 0.001 0.003
Renfrew/Paisley
Study Cohort
Increased 368 9.9 7,010 320 456.5 1.16 1.03, 1.31 1.17 1.04, 1.32 120 171.2 1.02 0.83, 1.24 1.03 0.84, 1.26 200 285.3 1.10 0.95, 1.29 1.10 0.95, 1.29
Maintained 2,409 64.6 45,596 2,050 449.6 1 Referent 1 Referent 771 169.1 1 Referent 1 Referent 1,279 280.5 1 Referent 1 Referent
Reduced 469 12.6 8,021 425 529.9 1.10 0.99, 1.22 1.08 0.97, 1.20 173 215.7 1.11 0.94, 1.32 1.14 0.95, 1.35 252 314.2 0.97 0.84, 1.12 0.97 0.84, 1.12
Quit 484 13.0 9,424 392 416.0 0.77 0.69, 0.86 0.75 0.67, 0.84 179 189.9 1.11 0.94, 1.31 1.05 0.88, 1.24 213 226.0 0.72 0.62, 0.83 0.73 0.63, 0.85
Ptrend <0.0001 <0.0001 0.18 0.46 <0.0001 <0.0001
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Determined by using competing risk models.
b Per 10,000 person-years.
c Adjusted for sex, social class, and cigarettes smoked at first screening and age at second screening.
d Adjusted for sex, social class, cigarettes smoked, and plasma cholesterol level at first screening and age, systolic blood pressure, body mass index (weight (kg)/height (m)2), diabetes, and preexisting coronary
heart disease at second screening.
D
oes
S
m
oking
R
eduction
R
educe
M
ortality
R
isk?
775
A
m
J
E
pidem
iol.
2013;178(5):770
–779
 at University of Stirling Library on February 21, 2014 http://aje.oxfordjournals.org/ Downloaded from 
as the main outcome measure, and 1 used the incidence of
stroke or myocardial infarction. There were clear differences
in the size and composition of the cohorts and in the duration
of follow-up. Four studies used the same deﬁnitions of
smoking groups and smoking reduction, and 2 studies used
different deﬁnitions. Although the Scottish and Israeli cohorts
were the most similar in terms of size, screening intervals,
and duration of follow-up, the apparent overall lack of beneﬁt
from smoking reduction for all-cause mortality found in the
Scottish analysis concurred with Norwegian (4), Danish (1),
and Korean (5) studies. However, the contrast is not as clear as
it might ﬁrst appear. In the Collaborative Study but not the
Renfrew/Paisley Study, heavy smokers who reduced their
smoking intensity had a signiﬁcantly lower mortality rate than
either smokers who maintained their cigarette consumption
or, surprisingly, light smokers who reduced their consumption.
This is similar to the ﬁndings in the Israeli cohort, in which
a signiﬁcant reduction in mortality risk was found among
heavy smokers but not among light smokers who reduced
their smoking intensity (6). Furthermore, although the analy-
sis of the combined Danish cohorts did not show a beneﬁt
from reducing smoking after 15.5 years of follow-up, the
risk of lung cancer among reducers was signiﬁcantly lower
after 18 years of follow-up (HR = 0.73, 95% CI: 0.54, 0.98)
(16). However, we did not ﬁnd that mortality from lung can-
cer was lower among those who reduced their smoking when
we combined the data from our 2 cohorts.
Given the abundant evidence for a dose-response relation-
ship between the lifetime number of cigarettes smoked and
subsequent morbidity and mortality, it would seem logical to
expect that reducing the number of cigarettes smoked would
lead to a lower mortality rate. The authors of the Israeli study
suggested the different results could be caused by insufﬁcient
length of follow-up of the cohorts in the previously reported
studies. This is given some support by the ﬁnding of reduced
lung cancer risk in the Danish pooled cohorts after a longer
period of follow-up (16). However, with more than 30 years
of follow-up, during which time more than 80% of the partici-
pants died, the Scottish cohort studies still did not show
unequivocal beneﬁt. The Scottish cohort studies had the
added beneﬁts of including both general and working popula-
tions of men and women, whereas the Israeli study included
only working men. Some explanation may lie in the contrast-
ing patterns of smoking reduction in the various studies. The
Israeli study showed that the main health beneﬁt appeared
to be among heavy smokers who reduced their smoking, a
ﬁnding mirrored in the Collaborative Study cohort but not the
Renfrew/Paisley Study cohort. A notable feature of the Israeli
cohort was the relatively high proportion of subjects who
were heavy smokers and who reduced the number of ciga-
rettes they smoked between the ﬁrst and second screenings.
This proportion represented 13.4% of the Israeli cohort com-
pared with 4.1% and 5.3% of the Collaborative Study and
Renfrew/Paisley Study cohorts, respectively, and 6.7% of the
much larger Korean cohort (5). This may, at least in part,
explain the observed differences in overall outcomes.
Crucially, all 6 cohorts lacked information about smoking
behavior and the reasons for any changes in smoking during
the follow-up period. Therefore, there is uncertainty about the
proportions of “reducers” in each cohort who sustained theirTa
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reported levels of reduction, subsequently quit smoking, or
resumed heavier smoking. A third screening, several years after
the second, was carried out on about half of the “reducers” in
the Danish cohort (2). In this third screening, approximately
50% of subjects had continued to smoke at a reduced level,
25% had quit smoking, and 25% had resumed heavy smoking.
We also know little about the behavior during follow-up
of the “maintainers,” with whom the “reducers” are compared.
All of the cohorts had substantial numbers of smokers who
increased their daily cigarette consumption between the 2
screenings, emphasizing the wide variation and unpredictability
of smoking behavior. Given the changes in smoking status
observed in all cohorts between the ﬁrst and second screenings,
it is inevitable that many of the “maintainers”will have changed
their cigarette consumption or will have quit smoking during
the years of follow-up. Consequently, the baseline against
which the “reducers” are compared is itself subject to con-
siderable uncertainty and could vary between the cohorts.
In a systematic review of the health beneﬁts of smoking
reduction, Pisinger and Godtfredsen (3) found that most of
the 25 studies meeting their criteria were small, with short
follow-up. They focused mainly on biological markers of
smoking intensity, cardiovascular risk factors, or intermedi-
ate outcomes such as the level of asthma control, the birth
weights of the babies of pregnant smokers, or hospital admis-
sions for chronic obstructive pulmonary disease. In small con-
trolled studies, many smokers were unable to sustain reduced
smoking levels. The reduction in biochemical markers of
smoking in these studies was, on average, less than would be
expected, indicating that some smokers may have compen-
sated for the reduced number of cigarettes by pufﬁng more
frequently or more intensely or by smoking more of each cig-
arette (17–19). Studies in the review that included smokers
who had signiﬁcantly reduced their smoking (often deﬁned as
a >50% reduction in baseline smoking) found an improve-
ment in respiratory symptoms and some cardiovascular risk
factors. However, the beneﬁts of less substantial smoking
reduction were much less clear (3).
Smoking reduction in itself, therefore, may not result in
health improvement; however, there is increasing evidence
Table 6. Odds Ratios of Surviving to Age 75 or 80 Years According to Changes in Smoking Intensity Between 2 Screenings of the Collaborative
(in 1970–1973 and 1977) and Renfrew/Paisley (in 1972–1976 and 1977–1979) Studies, Scotland
Smoking Intensity
Changes by Cohort Total No.
a
Survival to Age 75 Years Survival to Age 80 Years
No. % ORb 95% CI ORc 95% CI No. % ORb 95% CI ORc 95% CI
Collaborative
Study Cohort
Increased 207 97 46.9 0.69 0.50, 0.94 0.69 0.50, 0.94
Maintained 900 488 54.2 1 Referent 1 Referent
Reduced 146 77 52.7 1.0 0.70, 1.43 1.07 0.74, 1.54
Quit 262 172 65.6 1.68 1.25, 2.25 1.76 1.30, 2.38
Ptrend <0.0001 <0.0001
Renfrew/Paisley
Study Cohort
Increased 367 212 57.8 0.89 0.71, 1.12 0.88 0.69, 1.11 136 37.1 0.82 0.65, 1.03 0.80 0.63, 1.01
Maintained 2,393 1,455 60.8 1 Referent 1 Referent 987 41.2 1 Referent 1 Referent
Reduced 467 264 56.5 0.88 0.71, 1.08 0.87 0.70, 1.07 165 35.3 0.85 0.69, 1.05 0.83 0.67, 1.03
Quit 480 324 67.5 1.37 1.11, 1.70 1.44 1.16, 1.80 247 51.5 1.57 1.28, 1.92 1.64 1.33, 2.02
Ptrend 0.012 0.005 <0.0001 <0.0001
Collaborative and
Renfrew/
Paisley
Cohorts
Combinedd
Increased 574 309 53.8 0.81 0.67, 0.98 0.81 0.67, 0.97
Maintained 3,291 1,941 59.0 1 Referent 1 Referent
Reduced 613 341 55.6 0.91 0.76, 1.09 0.92 0.76, 1.10
Quit 741 495 66.8 1.49 1.25, 1.77 1.57 1.31, 1.87
Ptrend <0.0001 <0.0001
Abbreviations: CI, confidence interval; OR, odds ratio.
a Excludes 32 subjects who left the United Kingdom during the follow-up period (9 in the Collaborative cohort and 23 in the Renfrew/Paisley
cohort).
b Adjusted for sex, social class, and cigarettes smoked at the first screening and age at the second screening.
c Adjusted for sex, social class, cigarettes smoked, and plasma cholesterol level at the first screening and age, systolic blood pressure, body
mass index (weight (kg)/height (m)2), diabetes, and preexisting coronary heart disease at the second screening.
d Odds ratios are also adjusted for study.
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Table 7. Main Features of Prospective Cohort Studies Assessing the Long-Term Impact of Smoking Reduction
First Author, Year
(Reference No.)
Participants,
Country
Age at
Baseline,
years
No. of
Smokers
in Cohort
Categories of
Smoking
Intensity,
cigarettes/day
Definition of
Smoking
Reducer
First Year
Screened
Years to
Second
Screening
No. of
Reducers
Years of
Follow-Up
RR of Death
of Reducers
Versus
Maintainersa
95% CI
Gerber, 2012
(6)
Male civil
servants and
municipal
workers, Israel
≥40 4,633 1–10, 11–20,
and ≥21
Move to lower
group
1963 2 787 32 0.85 0.77, 0.95
Current paper Working men
and women,
Scotland
40–65 1,524 1–10, 11–20,
and ≥21
Move to lower
group
1970–1973 3–6 147 33 0.91 0.75, 1.10
Current paper Community
sample of men
and women,
Scotland
45–64 3,730 1–10, 11–20,
and ≥21
Move to lower
group
1972–1976 2–6 469 31–33 1.08 0.97, 1.20
Godtfredsen,
2002 (1)
Pooled
community
and
occupational
samples, men
and women,
Denmark
20–93 12,880 1–14 and ≥15 >50% Reduction
from ≥15/day
1967–1981 5–10 858 15.5
(mean)
1.02b 0.89, 1.17
Tverdal, 2006
(4)
Community
sample men
and women,
Norway
20–49 23,743 1–14 and ≥15 >50% Reduction
from ≥15/day
1974–1978 3–13 475 21.2
(mean)
1.02b 0.84, 1.22
Song, 2008 (5) Male civil
servants,
Korea
30–58 300,767 1–9, 10–19,
and ≥20
Move to lower
group
1990 2 39,045 9 Nonsignificant
reductions
in RR of stroke
or myocardial
infarctionb
Abbreviations: CI, confidence interval; RR, relative risk.
a All-cause mortality unless specified.
b Compared with heavy smokers who maintained the same smoking intensity.
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that it has a potentially important role as a step toward
smoking cessation. Smokers who are reducing their cigarette
smoking are more likely to report that they intend to quit,
want to quit, and are conﬁdent in their ability to quit (20, 21).
There is also good evidence that reducing smoking before
quitting with the aid of nicotine replacement therapy is just as
effective as abrupt cessation, and that the use of nicotine
replacement therapy when reducing smoking can increase the
rate at which smokers try and succeed in quitting (22). Nico-
tine replacement therapy was not available when participants
in the studies considered here reduced their smoking.
In conclusion, the long-term follow-up of these 2 Scottish
cohorts does not provide sufﬁcient evidence of beneﬁt to
endorse the Israeli conclusion that “reducing smoking intensity
may be advised for heavy smokers who cannot quit abruptly”
(6, p. 1011). Existing research does not provide useful guidance
for the level of reduction of cigarette consumption required to
confer meaningful health beneﬁts. On the other hand, con-
tinued smoking, even at low levels, clearly carries substan-
tially increased health risks (23). Reducing the frequency of
smoking should thus primarily be recommended as a short-
term step toward cessation.
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